| ALK

Privacy policy - Healthcare Professionals

Privacy notice for Healthcare Professionals

January 2025

The purpose of our website is to provide information about our company, products, and services. As part of your visit to our website, ALK (as the data controller) is required to provide you with certain information in accordance with Article 13 of the General Data Protection Regulation (GDPR) when processing information about you. Your privacy is important to ALK.

1. Identify and contact details about the data controller

ALK, as the data controller, is responsible for processing your personal data. Therefore, ALK solely determines the purposes and measures for processing your personal data.

 

Our contact information:

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: 45747576

Email: data.protection@alk.net

 

Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Gdanskgade 18

2150 Nordhavn

Denmark

Tel.: +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted email via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reach 
out to ALK or our Data Protection Officer.

2. Purpose of processing

We collect information about you to enable you to share information and receive updates.

3. Legal Basis for Processing Personal Data

Our legal basis for processing your personal data is compliance with legal obligations under GDPR Article 6(1)(c). Furthermore, some processing of your personal data will be based on your consent under GDPR Article 6(1)(a).

Additionally, we will process your data based on legitimate interests in relation to your feedback.

4. Data Sources

The personal data is obtained from following sources:

  • Contact form from our website
  • Sign up to receive promotional material
  • Engage with us for product evaluation
  • Engage with one of our sales representatives, professional affairs liaisons or call centres
  • Report an adverse event
  • Collaboration from scientific projects, hereunder Clinical Trials
  • Public sources
  • Specialised third parties

5. Categories of Personal Data Processed

Below, you can read about the data we collect from you:

  • Contact information
    • e.g., name, profession, title, address, telephone number, email, and place of work
  • Professional information
    • Qualifications, education, CV/resume, areas of expertise

6. Transfer of Personal Data

i.       ALK EMPLOYEES & EXTERNAL PROCESSORS

The recipients of your personal data will be employees of entities belonging to the ALK Group and external processors providing specific services and processing personal data on our behalf. They will receive your personal data only on a ‘need-to-know’ basis, subject to confidentiality obligations and after signing appropriate legal agreements.

ii.       INDEPENDENT THIRD PARTIES

When needed, we may disclose your personal data to independent third parties, such as attorneys, public authorities, or third-party auditors. In other situations, such as when using external shipment or payment providers, you will be involved in the process and, where relevant, offered choices regarding the transaction or payment method.

iii.       TRANSFERS OF DATA FROM EU/EEA TO THIRD COUNTRIES

If we share data from the EU/EEA with a company or ALK affiliate in a third country, we will apply contractual clauses that meet EU standards to ensure the receiving company handles personal data appropriately, unless the country where the company operates is already deemed by the EU to offer an adequate level of data protection. More information about such clauses is available here. If data transfers are required in other situations, we will inform you about the specific compliance measures in place to enforce EU law.

7. Retention Period

Your data will be stored as long as you are an HCP and maintain an account on the site or for as long as we have a legal or contractual obligation, whichever comes first

8. Data Subject Rights

a) Right to access

    You have the right to request access to your personal data held by ALK, as well as additional details.

b) Right to rectification

    You have the right to request correction of inaccurate or incomplete personal data.

c) Right to erasure

    You have the right to request the deletion of your personal data, except when retention is required by law.

d) Right to restrict processing

    You have the right to request the restriction of your personal data.

e) Right to object

    You have the right to object to the processing of your personal data.

f) Right to data portability

    In specific situations, you are entitled to receive your personal data in a structured, widely used, and machine-readable format.

 

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

9. Right to Complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information for the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 04.02.2025

Side effects

Privacy notice related to side effects

January 2025

The purpose of this information is to provide details about how ALK-Abelló A/S (ALK) processes personal data related to the reporting of side effects. In accordance with Article 13 of the General Data Protection Regulation (GDPR), ALK is required to provide you with certain information when processing your personal data in connection with the reporting of side effects.

1. Identify and contact details about the data controller

ALK, as the data controller, is responsible for the processing of your personal data. Therefore, ALK solely determines the purposes and measures for processing your personal data collected in connection with the evaluation of any complaints or side effects potentially related to an ALK-Abelló medical product.

 

Our contact information:

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: 45747576

Email:data.protection@alk.net

 

Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Gdanskgade 18

2150 Nordhavn

Denmark

Tel.: +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted email via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reach out to ALK or our Data Protection Officer.

2. Purpose of processing

  • To conduct a scientific evaluation of any complaints or side effects potentially related to an ALK medical product.
  • To include side effects in our global safety database, which is used for regular analyses.
  • To assess patterns associated with complaints, including side effects.

3. Legal Basis for Processing Personal Data

Processing personal data is necessary for compliance with legal obligations imposed on ALK, including the requirement to monitor the safety and efficacy of our medical products and to report side effects to regulatory authorities, in accordance with GDPR Article 6(1)(c) and GDPR Article 9(2)(j).

4. Data Sources

The personal data is obtained from the following sources:

  • Directly from you
  • From healthcare professionals such as your nurse, pharmacist, or doctor
  • From publicly available publications, websites, or social media

5. Categories of Personal Data Processed

Below, you can read about the data we collect from you.

  • Contact information
    • Name, address, telephone number, email address
  • Age, gender, and nationality
  • Ethnicity
  • Health information and medical products you are using
  • Information about side effect
  • Medical license number
  • Digital media profiles, e.g. LinkedIn

6. Transfer of Personal Data

i.       ALK EMPLOYEES & EXTERNAL PROCESSORS

The recipients of your personal data will be employees of entities belonging to the ALK Group and external processors providing specific services and processing personal data on our behalf. They will receive your personal data only on a ‘need-to-know’ basis, subject to confidentiality obligations and after signing appropriate legal agreements.

 

ii.       INDEPENDENT THIRD PARTIES

When needed, we may disclose your personal data to independent third parties, such as attorneys, public authorities, or third-party auditors. In other situations, such as when using external shipment or payment providers, you will be involved in the process and, where relevant, offered choices regarding the transaction or payment method.

 

iii.       TRANSFERS OF DATA FROM EU/EEA TO THIRD COUNTRIES

If we share data from the EU/EEA with a company or ALK affiliate in a third country, we will apply contractual clauses that meet EU standards to ensure the receiving company handles personal data appropriately, unless the country where the company operates is already deemed by the EU to offer an adequate level of data protection. More information about such clauses is available here. If data transfers are required in other situations, we will inform you about the specific compliance measures in place to enforce EU law.

7. Retention Period

Data is kept for as long as it is relevant or necessary in the global safety database.

8. Data Subject Rights

Under the General Data Protection Regulation (GDPR), you have certain data protection rights:

a) Right to access

    You have the right to request access to your personal data held by ALK, as well as additional details.

b) Right to rectification

    You have the right to request correction of inaccurate or incomplete personal data.

c) Right to erasure

    You have the right to request the deletion of your personal data, except when retention is required by law.

d) Right to restrict processing

    You have the right to request the restriction of your personal data.

e) Right to object

    You have the right to object to the processing of your personal data.

f) Right to data portability

    In specific situations, you are entitled to receive your personal data in a structured, widely used, and machine-readable format.

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

9. Right to Complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information for the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 04.02.2025

Visit on our website

Privacy notice related to your visit on our website

January 2025

The purpose of our website is to provide information about our company, products, and services. As part of your visit to our website, ALK-Abelló A/S (ALK) is required to provide you with certain information in accordance with Article 13 of the General Data Protection Regulation (GDPR) when processing information about you, such as when you visit our website. Your privacy is important to ALK.

1. Identify and contact details about the data controller

ALK, as the data controller, is responsible for the processing of your personal data. Therefore, ALK solely determines the purposes and measures for processing your personal data collected in connection with your visit to our website.

 

Our contact information:

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: 45747576

Email: data.protection@alk.net

 

Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Gdanskgade 18

2150 Nordhavn

Denmark

Tel.: +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted email via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reachout to ALK or our Data Protection Officer.

2. Purpose of processing

We collect information about your visit to our website to help us improve it. When you access our website, we request your consent to collect information about you.

3. Legal Basis for Processing Personal Data

We use consent or legitimate interests as our legal basis for processing the personal data listed below.

4. Data Sources

The personal data is obtained directly from you.

5. Categories of Personal Data Processed

Below, you can read about the data we collect from you.

  • Cookie consent
  • Visitor ID
  • IP-address (anonymized)
  • Location, date, and time of visit
  • The device you visit from

To learn more about our use of cookies, please read our Cookie notice.

6. Transfer of Personal Data

i       ALK EMPLOYEES & EXTERNAL PROCESSORS

The recipients of your personal data will be employees of entities belonging to the ALK Group and external processors providing specific services and processing personal data on our behalf. They will receive your personal data only on a ‘need-to-know’ basis, subject to confidentiality obligations and after signing appropriate legal agreements.

 

 

ii       INDEPENDENT THIRD PARTIES

When needed, we may disclose your personal data to independent third parties, such as attorneys, public authorities, or third-party auditors. In other situations, such as when using external shipment or payment providers, you will be involved in the process and, where relevant, offered choices regarding the transaction or payment method.

 

 

iii       TRANSFERS OF DATA FROM EU/EEA TO THIRD COUNTRIES

If we share data from the EU/EEA with a company or ALK affiliate in a third country, we will apply contractual clauses that meet EU standards to ensure the receiving company handles personal data appropriately, unless the country where the company operates is already deemed by the EU to offer an adequate level of data protection. More information about such clauses is available here. If data transfers are required in other situations, we will inform you about the specific compliance measures in place to enforce EU law.

7. Retention Period

Data will be kept only for as long as you wish or as long as we deem it relevant in the context of the business situation or service, whichever comes first.

8. Data Subject Rights

a) Right to access

    You have the right to request access to your personal data held by ALK, as well as additional details.

b) Right to rectification

    You have the right to request correction of inaccurate or incomplete personal data.

c) Right to erasure

    You have the right to request the deletion of your personal data, except when retention is required by law.

d) Right to restrict processing

    You have the right to request the restriction of your personal data.

e) Right to object

    You have the right to object to the processing of your personal data.

f) Right to data portability

    In specific situations, you are entitled to receive your personal data in a structured, widely used, and machine-readable format.

 

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

9. Right to Complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information for the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 04.02.2025

Visitors at ALK-Abelló A/S

Privacy notice for visitors at ALK-Abelló A/S

January 2025

As part of your visit, ALK-Abelló A/S (ALK) is required to provide you with certain information in accordance with Article 13 of the General Data Protection Regulation (GDPR) when processing information about you. Your privacy is important to ALK.

1. Identity and contact details of the data controller

ALK, as the data controller, is responsible for the processing of your personal data. Therefore, ALK alone sets the purpose and measures for processing your personal data, which are collected in connection with your visit to ALK.

 

Our contact information:

ALK-Abelló A/S

Address: Bøge Allé 1

2970 Hørsholm

Denmark

Tel.: 45747576

Email: data.protection@alk.net

 

Data Protection Officer:

Bech-Bruun Advokatpartnerselskab

CVR nr.: 38538071

Langelinie Allé 35

København Ø

Denmark

Tel. +45 72 27 30 02

Email: dpo.alk@bechbruun.com

Encrypted mail via: https://dpo.bechbruun.com/alk

 

If you have any questions regarding the processing of your personal data, you can always reach out to ALK or our Data Protection Officer.

2. Purpose of processing

We collect and process personal data about visitors on our premises for the following purposes:

  • Ensuring the security and safety of our premises
  • Granting access to authorized individuals only
  • Managing visitor registration and sign-in processes
  • Clarifying operational and security matters, such as access control on the premises, blocked escape routes, break-ins, vandalism, and similar incidents
  • Gathering facts for dispute resolution and clarification of technical issues.
  • Assisting in the investigation and prosecution of criminal offenses
  • Preventing and detecting criminal activities on our premises

3. Legal Basis for processing personal data

We process personal data in accordance with applicable laws and regulations. The legal basis for processing your personal data is as follows:

  • The Danish TV Surveillance Act and Executive order no. 788 of August 12. 2005, as amended.
  • The processing of personal data is necessary to protect the interests of ALK's employees according to Article 6(1)(d) of GDPR.
  • The processing is necessary to pursue the legitimate interests of the company. This include providing access to office facilities and other buildings, ensuring a safe and secure working environment, and optimizing operations, with accordance of Article 6(1)(f) of GDPR. If surveillance data reveals criminal acts, we use the Danish Data Protection Acts section 8(2) to (5) as our legal basis. ALK ensures visible signage about TV surveillance for employees, visitors, and vendors. The company has assessed that it processes personal data in accordance with an adequate and relevant balance of interests to achieve these legitimate interests.
  • The processing of personal data is necessary for the establishment, exercise, or defence of legal claims pursuant to Article 9(2)(f) of the GDPR.

4. Data source

The personal data we process about you is gathered from our TV surveillance and the information you provide when you check in and receive an access card.

5. Categories of personal data processed

We process the following personal data about you:

  • Name, workplace, email address, and telephone number
  • Photo and video clips without sound, captured on our premises
  • In special cases, processing of sensitive personal data may occur on our premises

6. Transfer of personal data

Your personal data will not be transferred to third countries outside of the EU or EEA. Our supplier, responsible for servicing and supporting CCTV surveillance, retains your personal information and is contractually bound to adhere to applicable data protection regulations. If required, we may disclose your personal information to legal professionals, advisors, and public authorities, including the police.

7. Data Retention

We will retain your personal data for the duration necessary to fulfill the purposes outlined in this privacy notice or as required by applicable laws and regulations. Specifically:

  • Personal data collected for security and safety purposes will be retained for a period of 30 days, unless a longer retention period is required by law or is necessary for the establishment, exercise, or defence of legal claims.
  • Personal data collected for the purpose of preventing and detecting criminal activities will be stored for 30 days, unless a longer retention period is required by law or is necessary for the investigation and prosecution of criminal offenses.
  • Personal data collected for operational and security matters, as well as for resolving disputes and technical issues, will be retained for a period of 30 days, unless a longer retention period is required by law or is necessary for the establishment, exercise, or defence of legal claims.

Once the retention period expires, we will securely delete or anonymize your personal data, unless further retention is required for legal, regulatory, or legitimate business purposes.

8. Data subject rights

a) Right to access

    You have the right to request access to your personal data held by ALK, as well as additional details.

b) Right to rectification

    You have the right to request correction of inaccurate or incomplete personal data.

c) Right to erasure

    You have the right to request the deletion of personal data, except when retention is required by law. In special circumstances, you may have the right to have your personal information deleted before our general deletion deadline occurs.

d) Right to restrict processing

    You have the right to request the restriction of the processing of your personal data. If you have the right to restrict processing, we may only process the information in the future – except for storage – with your consent or for the purpose of establishing, exercising, or defending legal claims, or to protect a person or vital societal interests.

e) Right to object

    You have the right to object to the processing of your personal data in certain circumstances. If you object to ALK's processing of your personal data based on specific reasons related to your particular situation, ALK, as a general rule, may no longer process the personal data. However, an exception exists if ALK demonstrates compelling legitimate grounds for the processing that outweigh your interests, rights, and freedoms, or if the processing is necessary for establishing, exercising, or defending legal claims.

f) Right to data portability

    In specific situations, you are entitled to receive your personal data in a structured, widely used, and machine-readable format.

 

If you would like to exercise any of these rights, please contact us using the contact details provided in section 1.

9. Right to complain

You have the right to file a complaint with the Data Protection Authority if you are dissatisfied with the way we process your personal data. Contact information for the Data Protection Authority can be found on their website.

If you have any questions or concerns about this privacy notice or our processing of your personal data, please contact us using the contact details provided in section 1.

Last updated: 04.02.2025

Privacy notice

Privacy notice

 

Visitors at ALK-Abelló A/S

Privacy notice for visitors at ALK-Abelló A/S

Learn More button icon

Visit on our website

Privacy notice related to your visit on our website

Learn More button icon

Side effects

Privacy notice related to side effects

Learn More button icon

Healthcare Professionals

Privacy notice for Healthcare Professionals

Learn More button icon

Newsletter

Privacy notice related to your subscription to our newsletter

Learn More button icon

Job application at ALK

Privacy notice related to your job application at ALK

Learn More button icon

CRM-Marketing

Privacy notice for CRM – Marketing

Learn More button icon

Shareholders, proxies and advisors

Privacy notice for shareholders, proxies and advisors

Learn More button icon

Investigators and research staff

Privacy notice for investigators and research staff participating in our clinical trials.

Learn More button icon

Last updated: 03.02.2026

Sustainability

Sustainable business practices

Our approach to a healthy society and planet
Links
Environmental
Social
Governance
2025 ANNUAL REPORT

Our approach to sustainability

At ALK, our mission to improve the lives of people with allergy goes hand in hand with conducting business responsibly and sustainably. Our sustainability reporting is aligned with the EU Corporate Sustainability Reporting Directive (CSRD) and the European Sustainability Reporting Standards (ESRS) and is subject to independent limited assurance. We support this framework as it promotes balanced, transparent, and comparable disclosures, aligned with our commitment to provide clear, reliable information to our stakeholders. Our sustainability information, covering ALK’s material environmental, social, and governance (ESG) matters, is disclosed as an integral part of our annual report.

Double materiality assessment

We acknowledge the various sustainability impacts, risks and opportunities associated with our business. As a key element of our CSRD reporting, we annually review our double materiality assessment (DMA). This process consists in identifying the material topics for our company, and is two-fold:

  • we assess how environmental, social and governance (ESG) issues affect our financial performance (financial materiality)
  • we analyse how ALK’s activities impact the environment and society (impact materiality).

Our material topics for 2025 remain unchanged and our focus continues to be on climate change and other environmental issues, our workforce and value chain workers, our consumers and end-users, and our business conduct.

Sustainability highlights

Graph

1 2022 and 2023 figures are not covered by the Independent Auditor’s limited assurance report on the Sustainability Statement

Learn more about our material environmental, social and governance topics:

Environmental
Social
Governance
2025 Annual Report
Read now

Previous sustainability reports

2024 annual report
Download
2023 annual sustainability report
Download
2022 annual sustainability report
Download
2021 annual sustainability report
Download
2020 annual sustainability report
Download

Partnering for sustainability

The challenges of climate change require commitments and partnerships

We have limited time for action and the private sector has a crucial role to play – every sector in every market must transform. By supporting international initiatives and engaging in partnerships, ALK contributes to promoting sustainable business practices globally.

ALK Alertline
ALK's whistleblower hotline enables employees, business partners and other stakeholders to report any serious and sensitive concern in a confidential and anonymous manner.
Report concern
Code of Conduct
ALK's Code of Conduct outlines the standards of behaviour that we expect from all ALK employees when interacting with stakeholders.
Learn more

Policy downloads

Diversity and inclusion
DOWNLOAD
Anti corruption
DOWNLOAD
Data ethics policy
DOWNLOAD
Third party code of conduct
DOWNLOAD
Tax policy
DOWNLOAD
Whistleblowing policy
DOWNLOAD
UK Modern Slavery Act statement 2025
DOWNLOAD
Code of Conduct
DOWNLOAD
Last updated: 20.02.2026

Collaboration & partnerships

Collaboration & partnerships

Collaboration and partnerships

Rasmus Just

Rasmus Just

Head of Global Business Development

Morten Jarlstrup

Morten Jarlstrup

Director, Global Business Development

Loic Derrien

Loic Derrien

Director, Global Business Development

Partnering interests

At ALK, partnerships are fundamental for our continued business development. We are fueled by commitment to innovate and continuously leverage the collective strengths of our partners to be able to deliver cutting edge treatment solutions to people living with allergy. Collaboration is key to our success, and we actively seek partners who share our commitment for developing advanced treatments.

By partnering with ALK, you will gain access to our extensive R&D and immunology expertise, as well as our proven track record of global clinical development and commercialisation. We are currently seeking innovative preclinical or clinical stage assets in allergic or inflammatory diseases, with a strong scientific rationale and an established IP position.

Who to contact

Name: Rasmus Just

Title: Head of Global Business Development

Contact details: RJUDK@alk.net

Last updated: 15.11.2024

Real-world evidence

Healthcare professionals

Real-world evidence

Links
REWEAL
REACT

From clinical to real-world evidence

Allergy immunotherapy (AIT) has evolved significantly over the last decade, triggered by the need for more evidence-based medicine. ALK has worked with the allergy community to develop the fields' most robust clinical trial programme, enrolling over 25,000 patients, enabling prescribing decisions to move from experience-based to evidence-based. But ideal-world evidence alone can only tell you so much.​

That is where our programme Real-world Evidence in Allergy (REWEAL) comes in, demonstrating how AIT works in the real world.

Why was REWEAL initiated?
Watch video

REWEAL – best of both worlds

Comprising patient data from independent sources across multiple countries, REWEAL brings physicians best-in-class real-world evidence. It reveals the benefits of AIT for people with allergy – from improvements in quality of life and reduced drug burden to disease modification and other long-term outcomes.

Our goal is to help inform the right treatment decision by providing the best in both clinical and real-world evidence.​

REWEAL – Real patients. Real questions. Answered

Have you ever

wondered if clinical

study outcomes of AIT 

are generalisable to 

the real world?

Time to REACT in AIT

With the REACT-study we aim to complement existing evidence from randomised controlled trials and address some key unanswered questions within AIT with real-world evidence. The study assesses the long-term effectiveness of AIT on both allergic rhinitis and asthma including more than 92,000 patients for up to nine years.

REACT study design
Read infographic
test
The REACT study, a retrospective cohort study
Go to publication
Subgroup analyses of the REACT study
Go to publication
Last updated: 18.11.2025

Our data

Healthcare professionals

Our data

Links
Clinical trials
Real-world evidence
Clinical data sharing

From clinical trials to real-world evidence

We focus on expanding the access for healthcare professionals and people living with allergies to evidence-based allergy immunotherapy as well as strengthening the evidence around burden of disease, disease modification, and new indications. Here you can explore more about our commitment to safety and efficacy of our treatment solutions for allergic disease, our key sublingual immunotherapy (SLIT) clinical trials and real-world evidence as well as sharing of our clinical data.

Avatar

Clinical trials

Our clinical trials commit to investigating the safety and efficacy of specific treatment of allergy and prevention of disease in a controlled setting. Learn more about our co-operations, areas of particular interest, and completed key SLIT randomised controlled trials.

Learn more
Avatar

Real-world evidence

In our real-world studies, we evaluate the safety and effectiveness of specific treatment of people living with allergy in an uncontrolled setting – the real world, where environmental, behavioural, and other every-day life factors are included. Real-world evidence is therefore increasingly used in healthcare decision making.

Learn more
Avatar

Clinical data sharing

In the spirit of transparency, and in compliance with industry guidelines, we share details of our clinical trials to help health care professionals and scientists improving the understanding of allergic disease and potential treatment options.

Learn more
Last updated: 11.12.2024

Clinical trials

Healthcare professionals

Clinical trials

Links
OUR KEY SLIT TRIALS
SHARING OF OUR DATA

Commitment to safety and efficacy

ALK has a commitment to invest in studying the safety and efficacy of its products. Our R&D department designs and manages our clinical trials in co-operation with university hospitals and allergy specialists. The clinical trials focus on the specific treatment and prevention of allergic disease. For our sublingual immunotherapy (SLIT)-tablets, a global development programme is conducted in collaboration with several partners.

When investigating allergy treatments and indications, we are particularly interested in whether patients’ symptoms and need for symptom-relieving medication have decreased, whether their quality of life has improved, if progression of the disease has slowed down or reversed as well as the overall cost-effectiveness versus existing products.

Our key SLIT-tablet randomised controlled trials

Our SLIT-tablets build on the legacy of subcutaneous immunotherapy, which was discovered in the early 20th century. In 2002, our SLIT-tablet for grass allergic rhinoconjunctivitis was tested in humans for the first time.

Below we have collected our completed key SLIT-tablet randomised, double-blinded, and placebo-controlled clinical trials investigating the safety and efficacy in grass, tree, ragweed, and house dust mite (HDM) allergic rhinoconjunctivitis, respectively. In addition, two of our completed key HDM SLIT-tablet trials investigated the safety and efficacy in allergic asthma.


Grass SLIT-tablet

Learn more

Tree SLIT-tablet

Learn more

Ragweed SLIT-tablet

Learn more

HDM SLIT-tablet


Grass SLIT-tablet

GT-08

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Long-term (five seasons)

Region: Europe

Age group: Adults

No. of participants: 634

ClinicalTrials: NCT00227279

EudraCT: 2004-000083-27

GT-12

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: Germany

Age group: Children and adolescents

No. of participants: 253

ClinicalTrials: NCT00408616

EudraCT: 2006-003415-46

P05238

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: North America

Age group: Adults

No. of participants: 439

ClinicalTrials: NCT00562159

P05239

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: North America

Age group: Children and adolescents

No. of participants: 345

ClinicalTrials: NCT00550550

P08067

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: North America

Age group: Children, adolescents, and adults

No. of participants: 1,501

ClinicalTrials: NCT01385371

GT-21/GAP

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Long-term (five seasons)

Region: Europe

Age group: Children and adolescents

No. of participants: 812

ClinicalTrials: NCT01061203

EudraCT: 2009-011235-12


Tree SLIT-tablet

TT-03

Disease area: Allergic rhinoconjunctivitis

Phase: II

Follow-up: 24 weeks

Region: Environmental exposure chamber (Europe)

Age group: Adults

No. of participants: 219

ClinicalTrials: NCT02481856

TT-04

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: Europe

Age group: Adolescents and adults

No. of participants: 634

EudraCT: 2015-004821-15

TT-06/TreeTop

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: Canada and Europe

Age group: Children and adolescents

No. of participants: 952

ClinicalTrials: NCT04878354

EudraCT: 2020-004372-17


Ragweed SLIT-tablet

P05233

Disease area: Allergic rhinoconjunctivitis

Phase: II/III

Follow-up: One year

Region: North America

Age group: Adults

No. of participants: 565

ClinicalTrials: NCT00783198

P05234

Disease area: Allergic rhinoconjunctivitis

Phase: II/III

Follow-up: One year

Region: North America and Europe

Age group: Adults

No. of participants: 784

ClinicalTrials: NCT00770315

EudraCT: 2008-003864-20

P008

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: Single-season

Region: North America and Europe

Age group: Children and adolescents

No. of participants: 1,025

ClinicalTrials: NCT02478398

EudraCT: 2014-004341-27


HDM SLIT-tablet

MT-02

Disease area: Allergic rhinoconjunctivitis and allergic asthma

Phase: II/III

Follow-up: One year

Region: Europe

Age group: Adolescents and adults

No. of participants: 604

ClinicalTrials: NCT00389363

EudraCT: 2006-001795-20

MT-04/MITRA

Disease area: Allergic asthma

Phase: III

Follow-up: Up to 78 weeks

Region: Europe

Age group: Adults

No. of participants: 834

ClinicalTrials: NCT01433523

EudraCT: 2010-018621-19

MT-06/MERIT

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: One year

Region: Europe

Age group: Adults

No. of participants: 992

ClinicalTrials: NCT01454544

EudraCT: 2011-002277-38

P003

Disease area: Allergic rhinoconjunctivitis

Phase: II

Follow-up: Up to 76 weeks

Region: Environmental exposure chamber (Europe)

Age group: Adults

No. of participants: 124

ClinicalTrials: NCT01644617

EudraCT: 2012-001855-38

TO-203-3-2

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: One year

Region: Japan

Age group: Adolescents and adults

No. of participants: 946

JapicCTI: 121848 (ENG)

P001

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: One year

Region: North America

Age group: Adolescents and adults

No. of participants: 1,482

ClinicalTrials: NCT01700192

MT-12/MATIC

Disease area: Allergic rhinoconjunctivitis

Phase: III

Follow-up: One year

Region: North America and Europe

Age group: Children

No. of participants: 1,460

ClinicalTrials: NCT04145219

EudraCT: 2019-000560-22

Compliance with guidelines

In compliance with industry guidelines, more information about all our clinical trials can be found via the freely public registries ClinicalTrials.gov and EudraCT as well as on the page Clinical data sharing.

Last updated: 19.03.2025
Subscribe to